Material Agreements

Cadre Holdings, Inc. entered into Incremental Facility Amendment to Credit Agreement and Guaranty Joinder with PNC Bank, National Association valued at $80 million (effective 2024-03-01).

“contemporaneous with the closing of the Alpha Acquisition on March 1, 2024 (the “Closing Date”), the Borrower, as borrower, entered into that certain Incremental Facility Amendment to Credit Agreement and Guaranty Joinder (the “Incremental Facility Amendment”), with the Company, as a Guarantor together with the other Guarantors party thereto, the Lenders party thereto, and PNC Bank, National Association, as Administrative Agent and Swingline Loan Lender”

Stronghold Digital Mining, Inc. entered into Electricity Sales and Purchase Agreements with Champion Energy Services, LLC valued at $425,000 deposit per subsidiary; estimated cost of power approximately $10-12/MWh plus wholesale pow (effective 2024-02-29).

“On February 29, 2024, each of Stronghold Digital Mining Inc.’s (the “Company”) wholly owned subsidiaries, Scrubgrass Reclamation Company, L.P. (“Scrubgrass”) and Panther Creek Power Operating, LLC (“Panther Creek”) entered into Electricity Sales and Purchase Agreements (collectively, the “ESPAs”) and Transaction Addendums (collectively, the “Addendums”) with Champion Energy Services, LLC (“Champion”).”

Future Health ESG Corp. entered into Roth Fee Modification Agreement with Roth Capital Partners LLC valued at Underwriters agreed to accept, in lieu of $300,000 cash fee, either shares of New Common Stock (mini (effective 2024-03-05).

“Also on March 5, 2024, the Company and Roth entered into a fee modification agreement (the "Roth Fee Modification Agreement" and, together with the Cantor Fee Modification Agreement, the "Fee Modification Agreements"), pursuant to which, among other things, Roth agreed to accept, in lieu of payment of the Roth Fee in cash at the Closing, either, in the Company’s sole discretion, (1) a certain number of shares of New Common Stock equal to the greater of (a) 10,000 and (b) the quotient obtained by dividing (x) $100,000 by (y) the VWAP (as defined in the Roth Fee Modification Agreement) of the New Common Stock over the three trading days immediately preceding the date of the initial filing of the re-sale registration statement on Form S-1 or F-1 (or any successor form, as applicable) to register the re-sale of such securities (the "Roth Fee Shares"), or (2) a non-refundable cash fee of $100,000.”

Future Health ESG Corp. entered into Cantor Fee Modification Agreement with Cantor Fitzgerald & Co. valued at Underwriters agreed to accept, in lieu of $8,700,000 deferred fee, either shares of New Common Stock (effective 2024-03-05).

“On March 5, 2024, the Company and Cantor entered into a fee modification agreement (the "Cantor Fee Modification Agreement"), pursuant to which, among other things, Cantor agreed to accept, in lieu of payment of the Cantor Deferred Fee in cash at the Closing, either, in the Company’s sole discretion, (1) a certain number of shares of the publicly traded common equity securities of the resulting public entity following the Company’s initial business combination (the "New Common Stock") equal to the greater of (a) 290,000 and (b) the quotient obtained by dividing (x) $2,900,000 by (y) the VWAP (as defined in the Cantor Fee Modification Agreement) of the New Common Stock over the three trading days immediately preceding the date of the initial filing of the re-sale registration statement on Form S-1 or F-1 (or any successor form, as applicable) to register the re-sale of such securities (the "Cantor Fee Shares"), or (2) a non-refundable cash fee of $2,900,000.”

Future Health ESG Corp. amended Amendment to Purchase and Sponsor Handover Agreement with Blufire Capital Limited valued at Amendment conditions Sponsor Handover on underwriters having $3,000,000 in cash or shares of Common (effective 2024-03-05).

“On March 5, 2024, Future Health, the New Sponsor and the Sponsor entered into an amendment to the Purchase and Sponsor Handover Agreement (the "First Amendment"), pursuant to which the Sponsor Handover is conditioned on, among other things, (i) the underwriters of Future Health’s initial public offering having in the aggregate either, at Future Health’s option, (a) $3,000,000 in cash or (b) a number of shares of Common Stock equal to the greater of (1) 300,000 and (2) the quotient obtained by dividing (x) $3,000,000 by (y) the three-day VWAP (as defined in the First Amendment) of the Common Stock over the three trading days immediately preceding the date of the initial filing of the re-sale registration statement on Form S-1 or F-1 (or any successor form, as applicable) to register the re-sale of such securities.”

Context Therapeutics Inc. amended Integral License Agreement with Integral Molecular, Inc. (effective 2024-02-29).

“Context Therapeutics Inc. (the “Company”) amended its collaboration and licensing agreement with Integral Molecular, Inc. (“Integral”) (the “Integral License Agreement”)”

GPGI, Inc. amended Amendment No. 2 to Third Amended and Restated Credit Agreement with JPMorgan Chase Bank, National Association, as administrative agent, and the lenders party thereto valued at not to exceed $40,000,000 (effective 2024-03-01).

“On March 1, 2024, CompoSecure Holdings, L.L.C. (“Holdings”), CompoSecure, L.L.C. (“CompoSecure”), Arculus Holdings, L.L.C. (“Arculus” and collectively with Holdings and CompoSecure, the “Companies”), JPMorgan Chase Bank, National Association, as administrative agent (“JPMC”), and the lenders party thereto, entered into Amendment No. 2 to Third Amended and Restated Credit Agreement (the “Second Amendment”).”

Cipher Digital Inc. amended Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., Canaccord Genuity LLC, Compass Point Research & Trading, LLC, Needham & Company, LLC, Stifel, Nicolaus & Company, Incorporated and Virtu Americas LLC valued at Amendment adds Stifel, Nicolaus & Company, Incorporated and Virtu Americas LLC as additional agents (effective 2024-03-06).

“On March 6, 2024, Cipher Mining Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) by and among Cantor Fitzgerald & Co., Canaccord Genuity LLC, Compass Point Research & Trading, LLC, Needham & Company, LLC, Stifel, Nicolaus & Company, Incorporated and Virtu Americas LLC.”

NEXTNRG, INC. entered into the "Note" with Next Charging, LLC valued at $165,000 (effective 2024-02-29).

“On February 29, 2024, EzFill Holdings, Inc. (the “Company”) and Next Charging, LLC (“Next”) entered into a promissory note (the “Note”) for the sum of $165,000 (the “Loan”) to be used for the Company’s working capital needs, which Note has an effective date of February 28, 2024.”

Blue Owl Credit Income Corp. amended Amendment No. 1 with The Bank of Nova Scotia, as Administrative Agent, State Street Bank and Trust Company, as Collateral Agent, Collateral Administrator and Document Custodian, and Hamburg Commercial Bank AG, Luxembourg Branch valued at converted $140,000,000 of revolving commitments to term commitments (effective 2024-03-01).

“On March 1, 2024 (the “Amendment Date”), Core Income Funding VI LLC (“Core Income Funding VI”), a subsidiary of Blue Owl Credit Income Corp. (the “Company”), (i) entered into Amendment No. 1 (the “Amendment No. 1” and the facility as amended, the “Credit Facility”), which amended that certain Credit Agreement, dated as of August 29, 2023”

Akero Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C. valued at approximately $299.4 million (effective 2024-03-05).

“On March 5, 2024, Akero Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C. as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell 11,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), to the Underwriters at a public offering price of $29.00 per share (the “ Offering ”).”

BridgeBio Pharma, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters valued at approximately $250.0 million (effective 2024-03-05).

“On March 5, 2024, BridgeBio Pharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 8,620,690 shares of the Company's common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $29.00 per share.”

BiomX Inc. entered into Agreement and Plan of Merger with Adaptive Phage Therapeutics, Inc. (effective 2024-03-06).

“On March 6, 2024, BiomX Inc., Inc., a Delaware corporation (the “Company” or “BiomX”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, BTX Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“First Merger Sub”), BTX Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Second Merger Sub”), and Adaptive Phage Therapeutics, Inc., a Delaware corporation (“APT”).”

Crypto Co entered into Securities Purchase Agreement with AJB Capital Investments, LLC valued at $159,000 (effective 2024-02-29).

“The Crypto Company (the “Company”) borrowed funds pursuant to the terms of a Securities Purchase Agreement (the “AJB SPA”) entered into with AJB Capital Investments, LLC (“AJB”), and issued a Promissory Note in the principal amount of $159,000 (the “AJB Note”) to AJB in a private transaction for a purchase price of $135,000, each dated as of February 29, 2024.”

Merus N.V. entered into Share Subscription Agreement with Gilead Sciences, Inc. (effective 2024-03-05).

“On March 5, 2024, we entered into a collaboration, option and license agreement (“Collaboration Agreement”) and Share Subscription Agreement (the “Subscription Agreement”) with Gilead Sciences, Inc. (“Gilead”).”

Merus N.V. entered into Collaboration Agreement with Gilead Sciences, Inc. valued at $56 million (effective 2024-03-05).

“On March 5, 2024, we entered into a collaboration, option and license agreement (“Collaboration Agreement”) and Share Subscription Agreement (the “Subscription Agreement”) with Gilead Sciences, Inc.”

Evofem Biosciences, Inc. entered into December Assignment Agreement with Aditxt, Inc. and certain holders of Company senior indebtedness notes (effective 2023-12-11).

“Aditxt entered into an assignment agreement, dated December 11, 2023 (the “December Assignment Agreement”) pursuant to which Aditxt and certain holders of Company senior indebtedness notes (the “Holders”) assigned their respective notes to Aditxt in consideration for the issuance, by Aditxt, of (i) an aggregate principal amount of $5.0 million in secured notes of the Company due on January 2, 2024 (the “January 2024 Secured Notes”), (ii) an aggregate principal amount of $8.0 million in secured notes of the Company due on September 30, 2024 (the “September 2024 Secured Notes”), (iii) an aggregate principal amount of $5.0 million in ten-year unsecured notes (the “Unsecured Notes”), and (iv) payment of $154,480 in respect of net sales of Phexxi in respect of the calendar quarter ended September 30, 2023 (the payment, together with the September 2024 Notes, the December 2023 Notes and the Unsecured Notes, as may have been amended from time to time, the “Notes”).”

Evofem Biosciences, Inc. entered into Agreement and Plan of Merger with Aditxt, Inc. and Adicure, Inc. (effective 2023-12-11).

“on December 11, 2023 the Company, Aditxt, Inc., a Delaware Corporation (“Aditxt”) and Adicure, Inc., a Delaware corporation and wholly-owned subsidiary of the Parent (the “Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), whereby the Merger Sub will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the “Merger”).”

Duolingo, Inc. amended First Amendment to the Lease with 5704 Penn Office, LLC valued at approximately $188,000 per month; approximately $394,000 per month; improvement allowance of up to a (effective 2024-03-04).

“On March 4, 2024, the Company entered into the First Amendment to the Lease (the “First Amendment”), which, among other things, increases the leased square footage by 110,008 square feet to a total of 148,266 square feet beginning on August 1, 2025, with an expiration date of April 30, 2036.”

Diamondback Energy, Inc. amended Fourteenth Amendment with Wells Fargo Bank, National Association, as administrative agent (effective 2024-03-06).

“On March 6, 2024, the Company and the Borrower entered into a fourteenth amendment (the “Revolving Amendment”) to the Second Amended and Restated Credit Agreement, dated as of November 1, 2013, with Wells Fargo Bank, National Association, as administrative agent (the “Administrative Agent”), and the lenders party thereto (as amended, supplemented or otherwise modified prior to the date of the Revolving Amendment and as further amended by the Revolving Amendment, the “Revolving Credit Agreement”).”

Diamondback Energy, Inc. entered into Term Loan Credit Agreement with Citibank, N.A., as administrative agent valued at $1.5 billion (effective 2024-02-29).

“On February 29, 2024 (the “Term Loan Effective Date”), Diamondback Energy, Inc., as guarantor (the “Company”), entered into a Term Loan Credit Agreement with Diamondback E&P LLC, as borrower (the “Borrower”), the lenders named therein and Citibank, N.A., as administrative agent (the “Term Loan Agreement”).”

SRAX, Inc. entered into Securities Purchase Agreement with certain accredited and institutional investor valued at $90,000 in principal amount of Original Issue Discount Convertible Debenture for $75,000 (effective 2024-03-05).

“On March 5, 2024 SRAX, Inc. (the “Company”) entered into definitive securities purchase agreements (the “Securities Purchase Agreement”) with a certain accredited and institutional investor (the “Purchasers”) for the purchase and sale of an aggregate of: (i) $90,000 in principal amount of Original Issue Discount Convertible Debenture (the “Debentures”) for $75,000 (representing a 20% original issue discount) (“Purchase Price”)”

ADIAL PHARMACEUTICALS, INC. entered into Inducement Agreement with a certain holder of the Company's warrants to purchase shares of common stock valued at approximately $3.5 million (effective 2024-03-01).

“On March 1, 2024, Adial Pharmaceuticals, Inc. (the “Company”) entered into a warrant inducement agreement (the “Inducement Agreement”) with a certain holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock”

Bone Biologics Corp entered into Securities Purchase Agreement with certain institutional investors valued at Combined offering price of $2.56 per Share and accompanying Warrant and $2.559 per Pre-Funded Warran (effective 2024-03-04).

“On March 4, 2024, Bone Biologics Corporation (the “Company”) priced a public offering (the “Offering”) of (i) 119,000 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), together with warrants (the “Warrants”) to purchase 119,000 shares of Common Stock at a combined public offering price of $2.56 per Share and accompanying Warrant and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 662,251 shares of Common Stock, together with Warrants to purchase 662,251 shares of Common Stock at a combined public offering price of $2.559 per Pre-Funded Warrant and accompanying Warrant.”

CORETEC GROUP INC. entered into Share Exchange Agreement with Core SS LLC valued at Member to sell all membership interests in Core Optics in exchange for 10,000,000 shares of Series C (effective 2024-03-01).

“On March 1, 2024, The Coretec Group, Inc. (the “Company”) entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Core Optics, LLC, a Virginia limited liability company (“Core Optics”), Core Optics Co., Ltd., a Republic of Korea corporation (“Operating Subsidiary”) and Core SS LLC, a Virginia limited liability company (the “Member”), which Member holds all outstanding membership interests in Core Optics.”

Scienture Holdings, Inc. entered into Stock Purchase Agreement with Superlatus Foods Inc. valued at $1.00 (effective 2024-03-05).

“On March 5, 2024, the Company entered in a Stock Purchase Agreement (“SPA”) with Superlatus Foods Inc. (the “Buyer”). Pursuant to the SPA, the Company sold all of the issued and outstanding stock (the “Stock”) of Superlatus Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Superlatus”), to the Buyer. The purchase price for the Stock was $1.00”

Scienture Holdings, Inc. entered into Subscription Agreement with Lafayette Energy Corp. valued at up to $5.0 million (effective 2024-02-29).

“On February 29, 2024, the Company’s wholly owned subsidiary Trxade, Inc. entered into a Subscription Agreement (the “Subscription Agreement”) with Lafayette Energy Corp., a Delaware corporation (“Lafayette”). Pursuant to the Subscription Agreement, Trxade, Inc. will, in two equal tranches, invest a total of up to $5.0 million in Lafayette in exchange for up to 2,000,000 shares of Lafayette’s newly created Series A Convertible Preferred Stock”

Owens Corning amended A/R Facility (Amended and Restated Receivables Purchase Agreement) with PNC Bank, National Association valued at $300,000,000 trade receivables securitization facility (effective 2024-03-01).

“On the Effective Date, the Company amended and restated its trade receivables securitization program (the “A/R Facility”) to, among other things, increase the A/R Facility limit from $280.0 million to $300.0 million, extend the scheduled maturity date from April 26, 2024 to February 28, 2025 and add certain subsidiaries of the Company as Originators (as defined below).”

Owens Corning amended Second Amended and Restated Credit Agreement with Wells Fargo Bank, National Association valued at $1,000,000,000 revolving credit facility (effective 2024-03-01).

“On March 1, 2024 (the “Effective Date”), Owens Corning (the “Company”), as borrower, entered into that certain Second Amended and Restated Credit Agreement (the “Credit Agreement”) with various financial institutions, as lenders, and Wells Fargo Bank, National Association, as administrative agent.”

Emergent BioSolutions Inc. amended Forbearance Agreement and Sixth Amendment to Amended and Restated Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and certain lenders valued at $270 million (effective 2024-02-29).

“On February 29, 2024, Emergent BioSolutions Inc. (the “Company”) entered into a Forbearance Agreement and Sixth Amendment to Amended and Restated Credit Agreement (the “Forbearance Agreement and Amendment”), among the Company, as borrower, certain subsidiaries of the Company, as guarantors, Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Administrative Agent”) and certain lenders party thereto (the “Lenders”).”

AUDIOEYE INC amended Amendment with SG Credit Partners, Inc. (effective 2024-03-05).

“On March 5, 2024, AudioEye, Inc. (the “Company”) and its wholly-owned subsidiary, Springtime, Inc. (together with the Company, the “Borrowers”), entered into an Amendment (the “Amendment”) to the Loan and Security Agreement (the “Loan Agreement”) dated as of November 30, 2023 with SG Credit Partners, Inc., a Delaware corporation (the “Lender”) to increase the Permitted Stock Repurchase (as defined in the Loan Agreement) to $3.5 million.”

HALLMARK VENTURE GROUP, INC. entered into Demand Promissory note with Alpha Strategies Trading Software, Inc. valued at $100,000 (effective 2024-03-01).

“On March 1, 2024, Hallmark Venture Group, Inc (the “Company”) issued a $100,000, 6% Demand Promissory note (the “Note”) to Alpha Strategies Trading Software, Inc., a non-affiliate of the Company.”

USBC, Inc. entered into Securities Purchase Agreement with Lind Global Fund II, LP valued at $14,400,000 (effective 2024-02-27).

“On February 27, 2024, Know Labs, Inc. (the “Company”) (a) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Lind Global Fund II, LP (“Lind”), pursuant to which the Company may issue Lind one or more senior convertible notes (the “Notes”) in the aggregate principal amount of up to Fourteen Million Four Hundred Thousand Dollars ($14,400,000)”

Greystone Housing Impact Investors LP amended Fifth Amendment to Credit Agreement with BankUnited, N.A., Bankers Trust Company (as Lenders), and BankUnited, N.A. (as Administrative Agent) valued at up to $10.0 million (effective 2024-03-04).

“On March 4, 2024, Greystone Housing Impact Investors LP (the “Partnership”) entered into a Fifth Amendment to Credit Agreement (the “Fifth Amendment”),”

KILROY REALTY CORP entered into Term Loan Agreement with JPMorgan Chase Bank, N.A., as administrative agent and a lender, and certain other financial institutions party thereto as lenders valued at $200 million senior unsecured term loan facility (effective 2024-03-06).

“On March 6, 2024, the Operating Partnership, as borrower, entered into a term loan agreement (the “Term Loan Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent and a lender, and certain other financial institutions party thereto as lenders.”

KILROY REALTY CORP entered into Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent and a lender, and certain other financial institutions party thereto as lenders valued at up to $1.1 billion (effective 2024-03-06).

“On March 6, 2024, Kilroy Realty, L.P. (the “Operating Partnership”), as borrower, entered into a fourth amended and restated credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent and a lender, and certain other financial institutions party thereto as lenders, which amends and restates and replaces in its entirety that certain third amended and restated credit agreement, dated as of April 20, 2021, by and among the Operating Partnership, JPMorgan Chase Bank, N.A., as administrative agent and a lender, and the other lenders named therein.”

TWIN DISC INC entered into Sale and Purchase Agreement with Katsa Oy valued at €21,000,000 (effective 2024-03-05).

“On March 5, 2024, TD Finland Holding OY (“TD Finland”), a wholly-owned subsidiary of Twin Disc, Incorporated (the “Company”), entered into a Sale and Purchase Agreement (the “Purchase Agreement”) with Katsa Oy (“Katsa”) to purchase all shares of capital stock of Katsa.”

VIAVI SOLUTIONS INC. entered into Interim Facilities Agreement with certain financial institutions (effective 2024-03-04).

“the Company and certain financial institutions named therein, among others, entered into an interim facilities agreement (substantially in the form of interim facilities agreement attached to the Commitment Letter) dated March 4, 2024 (the “Interim Facilities Agreement”)”

VIAVI SOLUTIONS INC. entered into Convertible Note Investment Agreement with certain affiliates of Silver Lake valued at $400 million aggregate principal amount of unsecured 4.00% / 4.50% Convertible Senior PIK Toggle Not (effective 2024-03-05).

“the Company and certain affiliates of Silver Lake named therein entered into an Investment Agreement, dated as of March 5, 2024 (the “Convertible Note Investment Agreement”) in respect of $400 million aggregate principal amount of unsecured 4.00% / 4.50% Convertible Senior PIK Toggle Notes”

VIAVI SOLUTIONS INC. entered into Commitment Letter with certain financial institutions (effective 2024-03-04).

“the Company and certain financial institutions party thereto entered into a commitment letter, dated as of March 4, 2024 (including all exhibits, annexes and schedules thereto, the “Commitment Letter”)”

VIAVI SOLUTIONS INC. entered into Co-operation Agreement with Spirent Communications plc (effective 2024-03-05).

“the Company, Spirent and Bidco entered into a Co-operation Agreement, dated as of March 5, 2024 (the “Co-operation Agreement”)”

SOLESENCE, INC. amended Second Amendment to Business Loan Agreement (Revolving Loan) with Beachcorp, LLC valued at Extended maturity from March 31, 2025 to October 1, 2025 (effective 2024-03-01).

“mendment”) with Beachcorp, LLC, which is also an affiliate of our controlling shareholder, Bradford T. Whitmore (“Beachcorp”),”

SOLESENCE, INC. amended Second Amendment to Business Loan Agreement (A&R Loan) with Beachcorp, LLC valued at Extended maturity from March 31, 2025 to October 1, 2025 (effective 2024-03-01).

“mendment”) with Beachcorp, LLC, which is also an affiliate of our controlling shareholder, Bradford T. Whitmore (“Beachcorp”),”

SOLESENCE, INC. amended Second Amendment to Business Loan Agreement (Term Loan) with Strandler, LLC valued at Extended maturity from March 31, 2025 to October 1, 2025 (effective 2024-03-01).

“the Company also entered into (i) a Second Amendment to Business Loan Agreement (the “Term Loan Agreement Amendment”) with Strandler, LLC”

SOLESENCE, INC. entered into Securities Purchase Agreement with Strandler, LLC valued at $6,000,000 (effective 2024-03-01).

“On March 1, 2024, Nanophase Technologies Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”), between the Company and Strandler, LLC (“Strandler”).”

CADENCE DESIGN SYSTEMS INC entered into Share Purchase Agreement with shareholders of BETA CAE Systems International AG valued at $1.24 billion (effective 2024-03-02).

“Cadence Design Systems, Inc., a Delaware corporation (“Cadence”), entered into a Share Purchase Agreement (the “Purchase Agreement”) with the shareholders of BETA CAE Systems International AG”

AMERICAS CARMART INC amended Amendment No. 6 to the Third Amended and Restated Loan and Security Agreement with a group of lenders valued at reduces the total permitted borrowings from $600 million to $340 million (effective 2024-02-28).

“On February 28, 2024, America’s Car-Mart, Inc., a Texas corporation (the “Company”), and its subsidiaries, Colonial Auto Finance, Inc., an Arkansas corporation (“Colonial”), America’s Car Mart Inc., an Arkansas corporation (“ACM”), and Texas Car-Mart, Inc., a Texas corporation (“TCM” and collectively with Colonial and ACM, the “Borrowers”), entered into Amendment No. 6 to the Third Amended and Restated Loan and Security Agreement (“Agreement”), dated as of September 30, 2019, by and among the Company, Colonial, ACM, TCM and a group of lenders, as previously amended on October 29, 2020, February 10, 2021, September 29, 2021, April 22, 2022 and February 22, 2023.”

EVO Transportation & Energy Services, Inc. amended Second Amendment with Antara Capital Master Fund LP and Corbin ERISA Opportunity Fund Ltd (effective 2024-02-28).

“On February 28, 2024, EVO Transportation & Energy Services, Inc., certain of its subsidiaries as guarantors, Antara Capital Master Fund LP and Corbin ERISA Opportunity Fund Ltd entered into the Second Amendment (the “Amendment”) to the Amended and Restated Senior Secured Loan and Executive Loan Agreement, dated December 23, 2022, among such parties.”

NORTECH SYSTEMS INC entered into Revolver with Bank of America, N.A. valued at $15 million (effective 2024-02-29).

“On February 29, 2024, we replaced our asset backed line of credit agreement with $15 million Senior Secured Revolving Line of Credit with Bank of America, N.A. (the “Revolver”).”

MICROVISION, INC. terminated Craig-Hallum Sales Agreement with Craig-Hallum Capital Group LLC valued at up to an aggregate of $35 million (effective 2024-03-05).

“On March 5, 2024, the Company and Craig-Hallum mutually agreed to terminate that certain At-The-Market Issuance Sales Agreement dated August 29, 2023 (the “Craig-Hallum Sales Agreement”) between the Company and Craig-Hallum, as sales agent.”